These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Cognitive-behavior therapy for obsessive-compulsive disorder: a systematic review of the last decade]. Prazeres AM; Souza WF; Fontenelle LF Braz J Psychiatry; 2007 Sep; 29(3):262-70. PubMed ID: 17713699 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial. Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832 [TBL] [Abstract][Full Text] [Related]
4. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Storch EA; Murphy TK; Goodman WK; Geffken GR; Lewin AB; Henin A; Micco JA; Sprich S; Wilhelm S; Bengtson M; Geller DA Biol Psychiatry; 2010 Dec; 68(11):1073-6. PubMed ID: 20817153 [TBL] [Abstract][Full Text] [Related]
5. D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial. Andersson E; Hedman E; Enander J; Radu Djurfeldt D; Ljótsson B; Cervenka S; Isung J; Svanborg C; Mataix-Cols D; Kaldo V; Andersson G; Lindefors N; Rück C JAMA Psychiatry; 2015 Jul; 72(7):659-67. PubMed ID: 25970252 [TBL] [Abstract][Full Text] [Related]
6. Cognitive-behavioral therapy for children who have obsessive-compulsive disorder. Piacentini J; Langley AK J Clin Psychol; 2004 Nov; 60(11):1181-94. PubMed ID: 15389618 [TBL] [Abstract][Full Text] [Related]
7. d-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder. de Leeuw AS; van Megen HJ; Kahn RS; Westenberg HG Eur Psychiatry; 2017 Feb; 40():38-44. PubMed ID: 27837671 [TBL] [Abstract][Full Text] [Related]
8. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647 [TBL] [Abstract][Full Text] [Related]
9. Successful Vortioxetine Monotherapy for an Adolescent With Treatment-Resistant Obsessive-Compulsive Disorder. Naguy A; Khraibut B; Al-Khadhari S Am J Ther; 2019; 26(6):e797-e799. PubMed ID: 31206363 [No Abstract] [Full Text] [Related]
18. Fear extinction learning as a predictor of response to cognitive behavioral therapy for pediatric obsessive compulsive disorder. Geller DA; McGuire JF; Orr SP; Small BJ; Murphy TK; Trainor K; Porth R; Wilhelm S; Storch EA J Anxiety Disord; 2019 May; 64():1-8. PubMed ID: 30852257 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder. Choi DC; Rothbaum BO; Gerardi M; Ressler KJ Curr Top Behav Neurosci; 2010; 2():279-99. PubMed ID: 21309114 [TBL] [Abstract][Full Text] [Related]
20. A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. Skapinakis P; Caldwell D; Hollingworth W; Bryden P; Fineberg N; Salkovskis P; Welton N; Baxter H; Kessler D; Churchill R; Lewis G Health Technol Assess; 2016 Jun; 20(43):1-392. PubMed ID: 27306503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]